Perioperative pain, analgesics and cancer-related outcomes: where do we stand?
Maria F RamirezFelipe P RangelJuan Pablo CataPublished in: Pain management (2021)
Cancer-related pain is one of the most common and debilitating symptoms among cancer patients. Undertreated cancer-related pain interferes with daily activities and increases morbidity and mortality. While opioids continue to play an essential role in treating moderate to severe cancer-related pain, they are associated with many adverse effects including misuse. While preclinical and retrospective studies have shown a negative association between opioid use and cancer outcomes, randomized control trials demonstrate that opioid use does not influence cancer recurrence. Additionally, analgesics and adjuvants used for perioperatively or chronic pain control are unlikely to improve oncological outcomes. This article focuses on the pharmacological management of cancer-related pain and offers an overview regarding the use of these medications perioperatively and the cancer outcomes.
Keyphrases
- chronic pain
- pain management
- papillary thyroid
- neuropathic pain
- stem cells
- clinical trial
- skeletal muscle
- double blind
- acute kidney injury
- type diabetes
- adipose tissue
- metabolic syndrome
- patients undergoing
- randomized controlled trial
- rectal cancer
- lymph node metastasis
- depressive symptoms
- childhood cancer
- weight loss
- minimally invasive
- insulin resistance